Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026)
Vireo Growth (VREOF) reported Depreciation & Amortization (CF) of $4.0 million for Q1 2026, up 566.67% on a YoY basis from $600000.0 in Q1 2025, and down 66.43% sequentially from $11.9 million in Q4 2025.
Vireo Growth (VREOF) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $4.0 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 566.67% year-over-year to $4.0 million; the trailing twelve-month figure through Mar 2026 stood at $19.5 million (up 679.43% YoY), and the FY2025 full-year result was $16.1 million, up 535.04% from the prior year.
- Depreciation & Amortization (CF) retreated to $4.0 million in Q1 2026, from $11.9 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $11.9 million in Q4 2025 to a low of $600000.0 in Q1 2025.
- A 5-year average of $1.7 million and a median of $776991.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slipped 29.08% in 2024 and jumped 1774.66% in 2025, its largest moves.
- Tracing VREOF's Depreciation & Amortization (CF) over 5 years: stood at $889195.0 in 2022, then dropped by 26.84% to $650503.0 in 2023, then retreated by 2.29% to $635583.0 in 2024, then jumped by 1774.66% to $11.9 million in 2025, then slumped by 66.43% to $4.0 million in 2026.
- Business Quant data shows VREOF's Depreciation & Amortization (CF) at $4.0 million in Q1 2026, $11.9 million in Q4 2025, and $2.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 239.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 119.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.04 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 22.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 676.10 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 7.20 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 172.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 4.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.00 Mn |
| Mar 31, 2026 | 4.00 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Dec 31, 2025 | 11.92 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Sep 30, 2025 | 2.34 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Jun 30, 2025 | 1.25 Mn |
| Mar 31, 2025 | 600,000.00 |
| Mar 31, 2025 | 600,000.00 |
| Dec 31, 2024 | 635,583.00 |
| Dec 31, 2024 | 635,583.00 |
| Sep 30, 2024 | 633,586.00 |
| Sep 30, 2024 | 633,586.00 |
| Jun 30, 2024 | 633,884.00 |
| Jun 30, 2024 | 633,884.00 |
| Mar 31, 2024 | 633,728.00 |
| Mar 31, 2024 | 633,728.00 |
| Dec 31, 2023 | 650,503.00 |
| Dec 31, 2023 | 650,503.00 |